FDA Rejects Moderna’s Flu Vaccine Application, Raising Industry Concerns

The Food and Drug Administration declined to review Moderna’s application for a new influenza vaccine, the company announced Tuesday, a decision that has prompted questions about the agency’s approach to pharmaceutical companies and vaccine policy.

Moderna disclosed the FDA’s rejection and released the agency’s letter, penned by Vinay Prasad, head of the FDA’s biologics division. Stephane Bancel, Moderna’s CEO, issued a statement criticizing the decision, stating it “does not further our shared goal of enhancing America’s leadership in developing innovative medicines.”

The core of the dispute centers on the control vaccine Moderna used when evaluating the effectiveness of its new influenza shot, which leverages the same messenger RNA (mRNA) technology as its Covid-19 vaccine. The FDA requires a comparison to an existing, approved influenza vaccine to demonstrate improvement.

According to Moderna, the FDA questioned the appropriateness of the comparator vaccine used in the clinical trial. The company maintains its chosen control was suitable, arguing it accurately reflected the current standard of care. The FDA, although, apparently disagreed, leading to the rejection of the application.

The decision arrives as the FDA faces increased scrutiny regarding its vaccine approval processes. Recent developments have introduced uncertainty into the approval process for updated Covid-19 boosters, according to U.S. Health officials. In February 2026, the FDA also granted full approval to Moderna’s Covid vaccine for children, though with limitations on eligibility, signaling a cautious approach to expanding vaccine access.

This is not the first recent approval of a Moderna vaccine to come with stipulations. The FDA recently approved a next-generation Covid vaccine from Moderna, but also with restrictions.

The rejection of Moderna’s influenza vaccine application is unusual, as the company took the step of publicly releasing the FDA’s communication. This level of transparency is not typical in regulatory proceedings and suggests a significant disagreement between the company and the agency.

As of Wednesday, February 11, 2026, the FDA has not publicly commented further on the decision, beyond the letter released by Moderna. The agency has not indicated whether Moderna can resubmit its application with a different control vaccine or what specific changes would be required for approval.